Aclaris Therapeutics Inc (ACRS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.50 (+1.85%), Market cap $0.66B, 52-week low–high $1.22 ~ $5.09.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-I
Financial statements, price targets, institutional (13F) holdings and related news for Aclaris Therapeutics Inc are updated in real time on BlackAll Trade.
Aclaris Therapeutics Inc trades at $5.50 (+1.85%). Real-time quotes and charts are available on BlackAll Trade.
Aclaris Therapeutics Inc has a market cap of about $0.66B.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United State